416 related articles for article (PubMed ID: 12499269)
1. Photodynamic therapy creates fluence rate-dependent gradients in the intratumoral spatial distribution of oxygen.
Busch TM; Wileyto EP; Emanuele MJ; Del Piero F; Marconato L; Glatstein E; Koch CJ
Cancer Res; 2002 Dec; 62(24):7273-9. PubMed ID: 12499269
[TBL] [Abstract][Full Text] [Related]
2. Depletion of tumor oxygenation during photodynamic therapy: detection by the hypoxia marker EF3 [2-(2-nitroimidazol-1[H]-yl)-N-(3,3,3-trifluoropropyl)acetamide ].
Busch TM; Hahn SM; Evans SM; Koch CJ
Cancer Res; 2000 May; 60(10):2636-42. PubMed ID: 10825135
[TBL] [Abstract][Full Text] [Related]
3. Fluence rate as a modulator of PDT mechanisms.
Henderson BW; Busch TM; Snyder JW
Lasers Surg Med; 2006 Jun; 38(5):489-93. PubMed ID: 16615136
[TBL] [Abstract][Full Text] [Related]
4. Treatment-induced changes in tumor oxygenation predict photodynamic therapy outcome.
Wang HW; Putt ME; Emanuele MJ; Shin DB; Glatstein E; Yodh AG; Busch TM
Cancer Res; 2004 Oct; 64(20):7553-61. PubMed ID: 15492282
[TBL] [Abstract][Full Text] [Related]
5. The effect of fluence rate on tumor and normal tissue responses to photodynamic therapy.
Sitnik TM; Henderson BW
Photochem Photobiol; 1998 Apr; 67(4):462-6. PubMed ID: 9559590
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of photodynamic therapy antitumor activity in mice by nitric oxide synthase inhibition is fluence rate dependent.
Henderson BW; Sitnik-Busch TM; Vaughan LA
Photochem Photobiol; 1999 Jul; 70(1):64-71. PubMed ID: 10420844
[TBL] [Abstract][Full Text] [Related]
7. Fluence rate-dependent intratumor heterogeneity in physiologic and cytotoxic responses to Photofrin photodynamic therapy.
Busch TM; Xing X; Yu G; Yodh A; Wileyto EP; Wang HW; Durduran T; Zhu TC; Wang KK
Photochem Photobiol Sci; 2009 Dec; 8(12):1683-93. PubMed ID: 20024165
[TBL] [Abstract][Full Text] [Related]
8. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy.
Seshadri M; Spernyak JA; Mazurchuk R; Camacho SH; Oseroff AR; Cheney RT; Bellnier DA
Clin Cancer Res; 2005 Jun; 11(11):4241-50. PubMed ID: 15930363
[TBL] [Abstract][Full Text] [Related]
9. Photofrin-mediated photodynamic therapy induces vascular occlusion and apoptosis in a human sarcoma xenograft model.
Engbrecht BW; Menon C; Kachur AV; Hahn SM; Fraker DL
Cancer Res; 1999 Sep; 59(17):4334-42. PubMed ID: 10485481
[TBL] [Abstract][Full Text] [Related]
10. Effect of photosensitizer dose on fluence rate responses to photodynamic therapy.
Wang HW; Rickter E; Yuan M; Wileyto EP; Glatstein E; Yodh A; Busch TM
Photochem Photobiol; 2007; 83(5):1040-8. PubMed ID: 17880498
[TBL] [Abstract][Full Text] [Related]
11. A Comparison of Dose Metrics to Predict Local Tumor Control for Photofrin-mediated Photodynamic Therapy.
Qiu H; Kim MM; Penjweini R; Finlay JC; Busch TM; Wang T; Guo W; Cengel KA; Simone CB; Glatstein E; Zhu TC
Photochem Photobiol; 2017 Jul; 93(4):1115-1122. PubMed ID: 28083883
[TBL] [Abstract][Full Text] [Related]
12. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors.
Bellnier DA; Gollnick SO; Camacho SH; Greco WR; Cheney RT
Cancer Res; 2003 Nov; 63(22):7584-90. PubMed ID: 14633671
[TBL] [Abstract][Full Text] [Related]
13. Photodynamic therapy of actinic keratosis at varying fluence rates: assessment of photobleaching, pain and primary clinical outcome.
Ericson MB; Sandberg C; Stenquist B; Gudmundson F; Karlsson M; Ros AM; Rosén A; Larkö O; Wennberg AM; Rosdahl I
Br J Dermatol; 2004 Dec; 151(6):1204-12. PubMed ID: 15606516
[TBL] [Abstract][Full Text] [Related]
14. Reduction of tumour oxygenation during and after photodynamic therapy in vivo: effects of fluence rate.
Sitnik TM; Hampton JA; Henderson BW
Br J Cancer; 1998 May; 77(9):1386-94. PubMed ID: 9652753
[TBL] [Abstract][Full Text] [Related]
15. Evidence for different mechanisms of EMT-6 tumor necrosis by photodynamic therapy with disulfonated aluminum phthalocyanine or photofrin: tumor cell survival and blood flow.
Chan WS; Brasseur N; La Madeleine C; van Lier JE
Anticancer Res; 1996; 16(4A):1887-92. PubMed ID: 8712717
[TBL] [Abstract][Full Text] [Related]
16. Photofrin photodynamic therapy can significantly deplete or preserve oxygenation in human basal cell carcinomas during treatment, depending on fluence rate.
Henderson BW; Busch TM; Vaughan LA; Frawley NP; Babich D; Sosa TA; Zollo JD; Dee AS; Cooper MT; Bellnier DA; Greco WR; Oseroff AR
Cancer Res; 2000 Feb; 60(3):525-9. PubMed ID: 10676629
[TBL] [Abstract][Full Text] [Related]
17. Foscan-based photodynamic treatment in vivo: correlation between efficacy and Foscan accumulation in tumor, plasma and leukocytes.
Maugain E; Sasnouski S; Zorin V; Merlin JL; Guillemin F; Bezdetnaya L
Oncol Rep; 2004 Sep; 12(3):639-45. PubMed ID: 15289849
[TBL] [Abstract][Full Text] [Related]
18. Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors.
Henderson BW; Gollnick SO; Snyder JW; Busch TM; Kousis PC; Cheney RT; Morgan J
Cancer Res; 2004 Mar; 64(6):2120-6. PubMed ID: 15026352
[TBL] [Abstract][Full Text] [Related]
19. Hypericin-photodynamic therapy (PDT) using an alternative treatment regime suitable for multi-fraction PDT.
Thong PS; Watt F; Ren MQ; Tan PH; Soo KC; Olivo M
J Photochem Photobiol B; 2006 Jan; 82(1):1-8. PubMed ID: 16203156
[TBL] [Abstract][Full Text] [Related]
20. Monitoring interstitial m-THPC-PDT in vivo using fluorescence and reflectance spectroscopy.
Kruijt B; van der Ploeg-van den Heuvel A; de Bruijn HS; Sterenborg HJ; Amelink A; Robinson DJ
Lasers Surg Med; 2009 Nov; 41(9):653-64. PubMed ID: 19802884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
